MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F, Garralda E, Wulf G, Almon C, Nabhan S, Aguado-Fraile E, He P, Romagnoli M, Hossain M, Narayanaswamy R, Sadou-Dubourgnoux A, Cooper M, Askoxylakis V, Burris H, Tabernero J. MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial. Nature Communications 2025, 16: 423. PMID: 39762248, PMCID: PMC11704051, DOI: 10.1038/s41467-024-55316-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsEnzyme InhibitorsFemaleHumansMaleMaximum Tolerated DoseMethionine AdenosyltransferaseMiddle AgedNeoplasmsS-AdenosylmethionineConceptsAdvanced malignanciesEvidence of clinical activityPaired tumor biopsiesTreatment-related toxicityPhase I trialPhase 1 trialFirst-in-humanLiver function testsProof-of-mechanismHomozygous MTAP deletionPlasma SAM concentrationsPartial responseConcentrations of S-adenosylmethionineTumor biopsiesI trialSafety profileMTAP deletionHomozygous deletionMAT2A inhibitionClinical activityPlasma concentrationsFunction testsPatientsSecondary objectivesMaximal reduction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply